Clinical Trials

Verified stories whose regulatory record supports clinical-trial access. Eligibility and enrollment are never guaranteed.

Filter clinical trials

Results

97 verified trial-access stories match your filters.

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Trial Watch: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

InvestigationalLater-Stage Human

Cancer type: Lymphoma
Trial identifier: NCT06337318
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-21

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-21

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06337318 (opens in a new tab) (Clinical-trial registry) NCT06337318 Load-bearing source NCT06337318
ClinicalTrials.gov — NCT06337318. NCT06337318.

Eligibility varies — review trial criteria.

Trial Watch: Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

InvestigationalLater-Stage Human

Cancer type: Endometrial (Uterine) Cancer
Trial identifier: NCT07198074
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed: 2026-08-21

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-21

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07198074 (opens in a new tab) (Clinical-trial registry) NCT07198074 Load-bearing source NCT07198074
ClinicalTrials.gov — NCT07198074. NCT07198074.

Eligibility varies — review trial criteria.

Trial Watch: A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

InvestigationalLater-Stage Human

Cancer type: Lung Cancer
Trial identifier: NCT05920356
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants ages 18 Years to 100 Years with Non-Small Cell Lung Cancer (NSCLC) who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-21

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-21

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT05920356 (opens in a new tab) (Clinical-trial registry) NCT05920356 Load-bearing source NCT05920356
ClinicalTrials.gov — NCT05920356. NCT05920356.

Eligibility varies — review trial criteria.

Trial Watch: Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

InvestigationalLater-Stage Human

Cancer type: Colorectal Cancer
Trial identifier: NCT07271355
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Appendix Carcinoma AJCC v8 who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-21

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-21

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07271355 (opens in a new tab) (Clinical-trial registry) NCT07271355 Load-bearing source NCT07271355
ClinicalTrials.gov — NCT07271355. NCT07271355.

Eligibility varies — review trial criteria.

Trial Watch: An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.

InvestigationalLater-Stage Human

Cancer type: Cervical Cancer
Trial identifier: NCT07776821
Trial phase: Phase 4

View trial details

Study design: Other / not applicable
Population: Participants ages 18 Years to 75 Years with Uterine Cervical Neoplasms who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed: 2026-08-20

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-20

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07776821 (opens in a new tab) (Clinical-trial registry) NCT07776821 Load-bearing source NCT07776821
ClinicalTrials.gov — NCT07776821. NCT07776821.

Eligibility varies — review trial criteria.

Trial Watch: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

InvestigationalLater-Stage Human

Cancer type: Lung Cancer
Trial identifier: NCT06151574
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Lung Cancer, Non-squamous, Non-small Cell who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-20

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-20

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06151574 (opens in a new tab) (Clinical-trial registry) NCT06151574 Load-bearing source NCT06151574
ClinicalTrials.gov — NCT06151574. NCT06151574.

Eligibility varies — review trial criteria.

Trial Watch: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

InvestigationalLater-Stage Human

Cancer type: Lymphoma
Trial identifier: NCT05675410
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants ages 5 Years to 60 Years with Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-20

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-20

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT05675410 (opens in a new tab) (Clinical-trial registry) NCT05675410 Load-bearing source NCT05675410
ClinicalTrials.gov — NCT05675410. NCT05675410.

Eligibility varies — review trial criteria.

Trial Watch: Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

InvestigationalLater-Stage Human

Cancer type: Colorectal Cancer
Trial identifier: NCT07775287
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Colorectal Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-20

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-20

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07775287 (opens in a new tab) (Clinical-trial registry) NCT07775287 Load-bearing source NCT07775287
ClinicalTrials.gov — NCT07775287. NCT07775287.

Eligibility varies — review trial criteria.

Trial Watch: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

InvestigationalLater-Stage Human

Cancer type: Leukemia
Trial identifier: NCT07504458
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants ages 18 Years to 71 Years with Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-19

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-19

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07504458 (opens in a new tab) (Clinical-trial registry) NCT07504458 Load-bearing source NCT07504458
ClinicalTrials.gov — NCT07504458. NCT07504458.

Eligibility varies — review trial criteria.

Trial Watch: Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

InvestigationalLater-Stage Human

Cancer type: Lung Cancer
Trial identifier: NCT07499674
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Lung Cancer, Lung Metastases who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-19

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-19

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07499674 (opens in a new tab) (Clinical-trial registry) NCT07499674 Load-bearing source NCT07499674
ClinicalTrials.gov — NCT07499674. NCT07499674.

Eligibility varies — review trial criteria.

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.